Sorrento Therapeutics Inc.

05/18/2022 | Press release | Distributed by Public on 05/18/2022 07:33

Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

Read this content
The text version of this document is not available. You can access the original document here.